Free Trial

Precipio Q4 2022 Earnings Report

Precipio logo
$6.58 +0.07 (+1.08%)
As of 03:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Precipio EPS Results

Actual EPS
-$2.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Precipio Revenue Results

Actual Revenue
$2.39 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Precipio Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

Precipio Earnings Headlines

Ignore every stock…
Stocks have been on a tear in 2024… And there’s plenty of great opportunities out there. But one expert says you should forget about EVERY stock for a moment and focus on an even bigger opportunity. The current GOLD supercycle You see, stocks are a dime a dozen for the most part… And, fortunately, they go up more than they go down. But every few decades, precious metals have a systematic supercycle that tends to dwarf the potential of just about anything else. The last time things aligned like this on gold it surged 536%
Precipio Reports Improved Financials Amid Challenges
See More Precipio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Precipio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Precipio and other key companies, straight to your email.

About Precipio

Precipio (NASDAQ:PRPO), a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.

View Precipio Profile

More Earnings Resources from MarketBeat